Drug Trial Radar · NCT07116928
Ganagliflozin on the Progression of Kidney Disease in Subjects With Type 2 Diabetes Mellitus and Chronic Kidney Disease
Last checked: Nov 20, 2026Latest source record: Nov 18, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
1,244
Planned (sponsor's estimate)
Start
Nov 30, 2025
Primary completion
Oct 30, 2031
Study completion Dec 30, 2031
Sponsor
- Lead sponsor
- Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Aug 12, 2025
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study aims to investigate the impact of adding Ganagliflozin tablets to the current background therapy on preventing the progression of kidney disease in subjects with type 2 diabetes and chronic kidney disease. The efficacy and safety will be evaluated by comparing the effects of Ganagliflozin tablets and placebo tablets added to the current background treatment over 120 weeks
Conditions
- T2DM (Type 2 Diabetes Mellitus)
- CKD - Chronic Kidney Disease
Interventions
ganagliflozinDrug
50 mg Once daily, 120 weeks
PlaceboDrug
50 mg Once daily, 120 weeks
Primary outcomes
What the sponsor says the trial is designed to measure.
- The average change in eGFR as measured by the total slope of eGFR from baseline to week 120Time frame: Baseline to Week 120
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Shanghai sixth People's Hospital
Shanghai, Shanghai Municipality, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.